WO1999001432A1 - Agent anti-diabetique - Google Patents

Agent anti-diabetique Download PDF

Info

Publication number
WO1999001432A1
WO1999001432A1 PCT/LV1998/000005 LV9800005W WO9901432A1 WO 1999001432 A1 WO1999001432 A1 WO 1999001432A1 LV 9800005 W LV9800005 W LV 9800005W WO 9901432 A1 WO9901432 A1 WO 9901432A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
agents
level
glucose
present
Prior art date
Application number
PCT/LV1998/000005
Other languages
English (en)
Russian (ru)
Inventor
Yanina Briede
Mara Stivrina
Egils Bisenieks
Janis Uldrikis
Natalia Makarova
Janis Poikans
Gunars Duburs
Karlis Heidemanis
Original Assignee
Latvias Organiskas Sintezes Instituts
Publiska Aktsiju Sabiedriba 'grindeks'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvias Organiskas Sintezes Instituts, Publiska Aktsiju Sabiedriba 'grindeks' filed Critical Latvias Organiskas Sintezes Instituts
Publication of WO1999001432A1 publication Critical patent/WO1999001432A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Definitions

  • the invention is in medicine, and in the case of drugs, they are intended for the treatment of diabetes and may be used in the treatment of diabetes.
  • the purpose of this invention is the creation of a new, efficient, affordable device that has a high efficiency and low efficiency.
  • the invention is implemented using alkoxyalkyl and phenoxyethyl esters of 4-aryl-2,6-dimethyl-1, 4-dihydrogen-pyridine-3,5-dicarboxylic acids below:
  • vasodilating activity was previously found.
  • Nifedipine (VII) and rhodydine (VIII) (phoroid) are very active, which, in the case of our invention, was already used to make the comparison.
  • the compounds of ⁇ -U fie indicated in the invention synthesize with a yield of 55-62%, by condencing the corresponding substituted benzaldehyde with an alcohol or pheno-aminestis.
  • Insulin deficiency in an organism causes a rupture in the metabolism of carbohydrates and lipids, and thereby hyperglycemia and hyperlipidemia.
  • the level of glucose at the end was divided by the introduction of C ⁇ and 3 hours after the introduction of the investigated substances, and also after 4 days.
  • 1_ ⁇ 50 are in the range of 400-4000 mg / kg;
  • Mentioned antidiabetic agents may be used as a substitute for insulin, which is only effective in injectable form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Cette invention concerne des esters alcoxyalcoylés et phénoxyalcoylés d'acides 4-aryl-2,6-diméthyl-1,4-dihydropyridin-3,5-dicarboniques qui correspondent à la formule générale (I). Ces composés peuvent être utilisés en médecine en qualité d'agents anti-diabétiques lors de divers stades de diabète sucré. Ces agents possèdent une action prolongée, une faible toxicité, et peuvent être utilisés afin de soigner des enfants comme des adolescents. A la différence de l'insuline, ces agents peuvent être administrés par voie perorale sous forme de cachets ou de pilules. Ces agents possèdent en outre un coût de production inférieur à celui de l'insuline.
PCT/LV1998/000005 1997-07-03 1998-06-30 Agent anti-diabetique WO1999001432A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-97-131 1997-07-03
LVP-97-131A LV12200B (lv) 1997-07-03 1997-07-03 Antidiabētisks līdzeklis

Publications (1)

Publication Number Publication Date
WO1999001432A1 true WO1999001432A1 (fr) 1999-01-14

Family

ID=19736322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/LV1998/000005 WO1999001432A1 (fr) 1997-07-03 1998-06-30 Agent anti-diabetique

Country Status (2)

Country Link
LV (1) LV12200B (fr)
WO (1) WO1999001432A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020977A1 (fr) * 2003-08-21 2005-03-10 Wisconsin Alumni Research Foundation Agents potentialisant la secretion d'insuline a base d'alpha-cetoglutarate
US10258498B2 (en) 2011-11-24 2019-04-16 Richter Gedeon Nyrt. 1,4-dihydropyridine derivatives with Hsp modulating activity

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1568740A (en) * 1976-10-30 1980-06-04 Bayer Ag 1,4-dihydro-2,6 dimenthyl - 4 - (3 - nitrophenyl) - 3,5-pyridinendicarboxylic acid ester several processes for its preparation and its use as a peripheral vasodilator
EP0184841A2 (fr) * 1984-12-14 1986-06-18 Nisshin Flour Milling Co., Ltd. Dérivés de 1,4-dihydropyridine, leurs procédés de préparation et les compositions pharmaceutiques les contenant
GB2168969A (en) * 1984-08-17 1986-07-02 Wyeth John & Brother Ltd 1,4-dihydro pyridines
EP0324626A1 (fr) * 1988-01-13 1989-07-19 Korea Research Institute of Chemical Technology Dérivés de 1,4-dihydropyridine
EP0330327A2 (fr) * 1988-02-25 1989-08-30 Pfizer Limited Dihydropyridines, leur préparation et leur utilisation comme PAF-antagonistes
GB2243608A (en) * 1988-03-08 1991-11-06 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of nifedipine
EP0657432A1 (fr) * 1993-12-10 1995-06-14 Bayer Ag 1,4-Dihydropyridines substitués par un groupement phényle avec une activité cérébrale
WO1995017186A1 (fr) * 1993-12-23 1995-06-29 Andrulis Pharmaceuticals Corporation Utilisation de la thalidomide pour le traitement du diabete sucre non insulino-dependant

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1568740A (en) * 1976-10-30 1980-06-04 Bayer Ag 1,4-dihydro-2,6 dimenthyl - 4 - (3 - nitrophenyl) - 3,5-pyridinendicarboxylic acid ester several processes for its preparation and its use as a peripheral vasodilator
GB2168969A (en) * 1984-08-17 1986-07-02 Wyeth John & Brother Ltd 1,4-dihydro pyridines
EP0184841A2 (fr) * 1984-12-14 1986-06-18 Nisshin Flour Milling Co., Ltd. Dérivés de 1,4-dihydropyridine, leurs procédés de préparation et les compositions pharmaceutiques les contenant
EP0324626A1 (fr) * 1988-01-13 1989-07-19 Korea Research Institute of Chemical Technology Dérivés de 1,4-dihydropyridine
EP0330327A2 (fr) * 1988-02-25 1989-08-30 Pfizer Limited Dihydropyridines, leur préparation et leur utilisation comme PAF-antagonistes
GB2243608A (en) * 1988-03-08 1991-11-06 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of nifedipine
EP0657432A1 (fr) * 1993-12-10 1995-06-14 Bayer Ag 1,4-Dihydropyridines substitués par un groupement phényle avec une activité cérébrale
WO1995017186A1 (fr) * 1993-12-23 1995-06-29 Andrulis Pharmaceuticals Corporation Utilisation de la thalidomide pour le traitement du diabete sucre non insulino-dependant

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020977A1 (fr) * 2003-08-21 2005-03-10 Wisconsin Alumni Research Foundation Agents potentialisant la secretion d'insuline a base d'alpha-cetoglutarate
US7863301B2 (en) 2003-08-21 2011-01-04 Wisconsin Alumni Research Foundation Potentiators of insulin secretion
US8507557B2 (en) 2003-08-21 2013-08-13 Wisconsin Alumni Research Foundation Potentiators of insulin secretion
US10258498B2 (en) 2011-11-24 2019-04-16 Richter Gedeon Nyrt. 1,4-dihydropyridine derivatives with Hsp modulating activity
US10660789B2 (en) 2011-11-24 2020-05-26 Richter Gedeon Nyrt. 1,4-dihydropyridine derivatives with HSP modulating activity

Also Published As

Publication number Publication date
LV12200B (lv) 1999-04-20
LV12200A (lv) 1999-01-20

Similar Documents

Publication Publication Date Title
DE60019435T2 (de) Therapeutische anwendung von polymere die gamma-hydroxybutyrat enthalten
Al-Hader et al. Hyperglycemic and insulin release inhibitory effects of Rosmarinus officinalis
NL9002720A (nl) Blokkeermiddelen van edrf-effect of -vorming ter behandeling van shock.
Selye et al. On the therapeutic value of adrenal cortical hormones in traumatic shock and allied conditions
DE60223551T2 (de) Mittel zu linderung von hyperglykämie nach dem essen
RU2067862C1 (ru) Средство для ингибирования образования аллофильных и ксенофильных антител для уменьшения реакций отторжения организма реципиента на пересаженный орган
DE3511609C2 (fr)
DE3879258T2 (de) Praeparat gegen ulcus.
WO1999001432A1 (fr) Agent anti-diabetique
DE60217369T2 (de) Pharmazeutische zusammensetzung enthaltend gamma-butyrobetain
DE1900772C3 (de) Salz aus N,N-Dimethylbiguanid und p-Chlorphenoxyessigsäure sowie dieses enthaltende Arzneimittel
CN107573393A (zh) 一种低糖基化普鲁宁的制备及其在抗炎平喘药物中的应用
US20090263466A1 (en) Herbal composition for treatment of hyperlipidemia and the inhibition of myocardial infarction
RU2197259C1 (ru) Антидиабетическое средство
Prakasam et al. Glycaemic control by Casearia esculenta–a short duration study in albino rats
KR0173814B1 (ko) 해당화 근부 추출물을 포함하는 건강보조식품
DE2135492C3 (de) Gewinnung eines Anacardhim occidentale L-Rindenextraktes mit antihypertensiver Wirkung
DE2462813C2 (de) Verwendung von acylierten Anilinobuttersäuren bzw. deren Salzen
RU2337698C1 (ru) Противодиабетическое средство с гиполипидемической активностью для лечения и профилактики сахарного диабета ii типа
JPH04124139A (ja) 血糖降下機能剤の製造方法
DE1695907C3 (de) Verwendung von 3,5-Dimethyl-l,2oxazinon-(6)
DE2408372A1 (de) Pharmazeutische zubereitungen auf der grundlage von hippursaeurederivaten
FR1042M (fr)
CA2070114C (fr) Methode de traitement de l'hyperglycemie
DE2219874C3 (de) 2-Dimethylaminoäthanolsalz des L-N hoch 2, N hoch 5 -Diacetylornithins und Verfahren zu seiner Herstellung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999506941

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA